36/100
Dementia cases are projected to triple globally by 2050, largely driven by an aging population. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
28,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Compared to persons without IDD, cumulative incidence of dementia was on average 4.27 and 5.33 times higher in persons with Non-DS IDD and DS respectively and period prevalence of dementia was on average 4.87 and 5.93 times higher in persons with Non-DS IDD and DS respectively. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Type 2 diabetes (T2DM) significantly increases the risk of dementia due to overlapping metabolic, molecular, and genetic factors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aging population is increasingly affected by both diabetes mellitus and hearing loss, two conditions that often coexist and can significantly impact quality of life. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The findings indicate that the burden of dementia is rising in East and Southeast Asia, with women showing a higher burden across all indicators. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BACKGROUNDTraffic-related air pollution (TRAP) is a risk factor for Alzheimer disease (AD), where unresolved brain inflammation has been linked to deficits in the levels of free lipid mediators that enable the resolution of inflammation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
An integrated TCD-NIRS protocol was feasible in these patient groups to measure NVC, but less-so in delirium. 3 key findings →
Design: post-hoc analysis Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of the 74 patients examined, 19 (25.7%) experienced delirium, while 55 (74.3%) showed no symptoms of delirium. 5 key findings →
Participants: 74 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The role of inflammation in neurological disorders is increasingly recognised. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes and Alzheimer disease (AD)-two age-related diseases-are both increasing in prevalence, and numerous studies have demonstrated that patients with diabetes have an increased risk of developing AD compared with healthy individuals. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A host of diabetes-related insults to the central nervous system (CNS) have been clearly documented in type-1 and -2 diabetic patients as well as experimental animal models. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The hypothesis is forwarded that sporadic late-onset Alzheimer disease is caused by non-insulin dependent diabetes mellitus which is confined to the brain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is a serious problem that affects millions of people in the United States alone. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The incidence of Alzheimer disease (AD) and diabetes mellitus (DM) is increasing at an alarming rate and has become a major public health concern worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is a cause of death and disability and can lead to tauopathy-related dementia at an early age. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity and type 2 diabetes mellitus (T2DM) convey an increased risk for developing dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is a major environmental risk factor for subsequent development of Alzheimer disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive decline may lead to dementia whose most frequent cause is Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It is possible to identify risks or protective factors against dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
It may be that risk and protective factors vary with age, however, in the absence of prophylactic treatment it seems likely that the maintenance of a healthy lifestyle may represent the best option with regard to the prevention of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The hippocampal formation, which contains high levels of adrenal steroid receptors, is vulnerable to insults such as stroke, seizures, and head trauma, and it is also sensitive and vulnerable to the effects of stress. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Current research indicates that neurocognitive sequelae following critical illness are common, may be permanent, and are associated with impairments in daily function, decreased quality of life, and an inability to return to work. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anxiety symptoms were common and significantly related to ADL and additional neuropsychiatric problems in this sample. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Diabetes in the elderly is a growing public health burden. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 3,795 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Air Pollution as an Environmental Risk Factor for Alzheimer's Disease and Related Dementias
- Wrist actigraphy
- The impact of presentation modality on cognitive test performance for adults with hearing loss
- Estrogen-dependent hippocampal wiring as a risk factor for age-related dementia in women
- Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia
- Impact of air pollution and climate change on mental health outcomes: an umbrella review of global evidence
- Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease
- Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
- Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction
- From Anxiety, Depression to Major Neurocognitive Disorders: Exploring Their Association With the Risk Factors for Dementia
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,980 records, built mostly from automated pulls of Europe PMC (62.8% of the library) and OpenAlex (17.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,038 records (3.6% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →